Suppression

(redirected from Myelosuppression)
Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.

suppression

[sə′presh·ən]
(computer science)
Removal or deletion usually of insignificant digits in a number, especially zero suppression.
Optional function in either on-line or off-line printing devices that permits them to ignore certain characters or groups of characters which may be transmitted through them.
(electronics)
Elimination of any component of an emission, as a particular frequency or group of frequencies in an audio-frequency of a radio-frequency signal.

Suppression

 

in genetics, a phenomenon that prevents the appearance of a character resulting from mutation and that causes partial or complete restoration of the normal phenotype.

Intragenic suppression is caused by a second (suppressor) mutation in the same gene in which the first (direct) mutation occurred. Intergenic suppression is caused by a second mutation in other genes that are located at a considerable distance from the suppressed gene. In intragenic suppression, a protein coded by a given gene can reacquire functional activity, although its original structure, in contrast to true reverse mutation, or reversion, is not restored. In intergenic suppression, the normal phenotype may be restored in some cases owing to mutations that permit other means of metabolism which do not require the functioning of the given gene. In other cases, the normal phenotype may be restored as a result of mutations that alter the process by which the genetic information of the mutant gene is realized.

The phenomenon of suppression, first discovered in 1920 by the American geneticist A. H. Sturtevant, is used to study the genetic code and other aspects of molecular genetics.

REFERENCE

Stent, G. Molekuliarnaia genetika. Moscow, 1974. Chapter 6. (Translated from English.)

I. I. TOLSTORUKOV

References in periodicals archive ?
In one patient series, IBD patients with impaired TPMT activity accounted for half of all cases of leukopenia and 27% of all cases of severe myelosuppression during 87 months of 6-MP or azathioprine therapy
Outside of a clinical trial, concomitant use of Xofigo in patients on chemotherapy is not recommended due to the potential for additive myelosuppression.
Historically, dose limiting toxicity observed with VAL-083 was limited to myelosuppression.
One of the findings observed in clinical trials to date is the lack of myelosuppression seen with other treatments.
5 million in a Series A financing led by MedImmune Ventures that will enable it to advance its lead clinical candidate into clinical trials for the potential treatment of chemotherapy induced myelosuppression.
I look forward to helping the G1 team advance its product candidate for the potential treatment of chemotherapy-induced myelosuppression into clinical trials and expanding the company's novel CDK4/6 platform into other indications.
G1's lead clinical candidate is a proprietary, potent and selective cyclin-dependent kinase (CDK) 4/6 inhibitor that has been evaluated in a number of pre-clinical studies for the potential treatment of chemotherapy-induced myelosuppression.
Kwok Wong of the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute, to address the serious complications of myelosuppression in patients undergoing chemotherapy treatment.
AmpliMed's strategy is to develop anti-cancer drugs with novel mechanisms of action designed to overcome some of the limitations, such as myelosuppression, multi-drug resistance and cardiac toxicity, frequently associated with current cancer therapies.